Recommended

Teva close to API business sale
Streamlined rAAV purification enables efficient upstream analytics – access now
First new IPF treatment in US for a decade
Webinar: Radiopharmaceuticals’ time-to-result challenge
AstraZeneca/Daiichi cancer drug boost
Takeda to move away from cell therapy
GSK appoints new CEO
news

J&J’s Tremfya secures two paediatric psoriasis approvals from FDA

0
SHARES

The US FDA approvals make the drug the first IL-23 inhibitor to be licensed for two common skin conditions.

johnson & Johnson Temfya

The Food and Drug Administration (FDA) has approved Johnson & Johnson’s Tremfya (guselkumab) to treat paediatric plaque psoriasis and active psoriatic arthritis, making it the first IL-23 inhibitor to gain such a licence in the US.

 

Reserve your FREE place

 


Address the time-to-result challenge posed by short shelf-life radiopharmaceuticals.

20 November 2025 | 3:00 PM GMT | FREE Virtual Panel Discussion

This webinar showcases the Growth Direct System; an RMM (Rapid Microbial Method) that improves on traditional membrane filtration, delivering increased accuracy, a faster time to result, enhanced data integrity compliance, and more control over the manufacturing process.

Key learning points:

  • Understand the benefits of full workflow microbiology quality control testing automation in radiopharmaceutical production
  • Learn about ITM’s implementation journey and considerations when evaluating the technology
  • Find out how the advanced optics and microcolony detection capabilities of Growth Direct® technology impact time to result (TTR).

Don’t miss your chance to learn from experts in the industry – Register for FREE

 

The subcutaneous injection monoclonal antibody is now indicated for children six years old and over who weigh at least 40kg with moderate to severe plaque psoriasis (PsO), and are candidates for systemic therapy or phototherapy, or who have active psoriatic arthritis (PsA).

Approval of Tremfya was based on data from the phase III PROTOSTAR study, presented at the 2025 AAD Annual Meeting.

“despite advancements in the treatment of paediatric plaque psoriasis and active psoriatic arthritis, there continues to be a significant gap in available therapies for these debilitating immune-mediated diseases”

At Week 16, 66 percent of moderate to severe plaque PsO patients attained skin clearance. This was compared to 16 percent of patients given placebo treatment. Furthermore, almost 40 percent of participants achieved complete clearance, versus just four percent who did so on placebo.

Additionally, the FDA’s approval was supported by evidence from pharmacokinetic extrapolation analyses from trials including the phase III VOYAGE 1 and 2 studies in adults with moderate to severe plaque PsO, as well as the DISCOVER 1 and 2 studies.

Significance of the approval

Dr Vimal Hasmukh Prajapati, Clinical Associate Professor, University of Calgary and study investigator, explained that “despite advancements in the treatment of paediatric plaque psoriasis and active psoriatic arthritis, there continues to be a significant gap in available therapies for these debilitating immune-mediated diseases that impact a child’s physical and emotional wellbeing during critical years”.

Therefore, authorisation of Tremfya represents “an important step forward” for patients, according to Brandee Pappalardo, PhD, Vice President, Medical Affairs, Dermatology & Rheumatology, Johnson & Johnson Innovative Medicine.

The FDA’s latest decision adds to the agency’s earlier authorisations of Tremfya in adults with moderate to severe plaque PsO in 2017 and active PsA in 2020.

The drug has also shown long-term promise for ulcerative colitis patients, as seen in phase III trials released in May.

Share via
Share via